Eculizumab Changed the Course of Atypical Hemolytic Uremic Syndrome Eculizumab Changed the Course of Atypical Hemolytic Uremic Syndrome
The approval of the monoclonal antibody eculizumab for treatment of atypical hemolytic uremic syndrome led to significant improvements in outcomes, according to a study of French patients presented June 3 at American Transplant Congress 2019 in Boston.Reuters Health Information
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Nephrology News Source Type: news
More News: France Health | Hemolytic Uremic Syndrome (HUS) | Politics | Study | Surgery | Transplant Surgery | Transplants | Urology & Nephrology